Analysis Hemogenyx Pharmaceuticals PLC (HEMO)
6/4/2024
Analysis of Hemogenyx Pharmaceuticals PLC (HEMO)
Hemogenyx Pharmaceuticals PLC (HEMO) has been showing some volatility in its stock price recently. The RSI indicator has been fluctuating around the mid-range, indicating a balanced market sentiment. The MACD indicator has been slightly negative, but the MACD histogram has shown some positive movements.In terms of moving averages, the stock price has been below the SMA, EMA, and WMA, indicating a bearish trend. However, the price has been hovering around these moving averages, suggesting a possible consolidation phase.
Overall, HEMO seems to be in a consolidation phase with some bearish bias. Traders and investors may want to closely monitor the stock for any breakout or reversal signals before making any trading decisions.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows growth compared to the EPS of $1.17 from the same quarter a year ago, as predicted by 27 analysts.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This indicates an increase from the EPS of $1.35 in the same quarter last year, as forecasted by 26 analysts.
3. Looking at the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects growth compared to the EPS of $5.67 from the previous fiscal year, as projected by 40 analysts.
4. For the next fiscal year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests an increase from the EPS of $6.10 in the current fiscal year, as estimated by 40 analysts.
Overall, the analysts are generally optimistic about the company's future earnings per share, with growth expected in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate growth expected in both the quarterly and annual sales figures.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest that the company has been experiencing strong growth in the past, but analysts expect the growth rate to moderate slightly in the coming years, although it is still expected to be healthy.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast of $201.43 and an average forecast of $204.58. However, it's worth noting that there is a wide range of forecasts, from a low of $164 to a high of $275. The current price of the security is $192.25, which is below both the median and average forecasted prices.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a decrease in quarterly revenue and earnings growth year over year.
Moving on to stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.
Valuation metrics show a high PEG ratio and price-to-book ratio, with the company's market capitalization and enterprise value being substantial. The price-to-sales ratio and enterprise multiples indicate the company's valuation in relation to its revenue and EBITDA.
The stock price summary includes beta, moving averages, and the range of prices over the past year. Dividends and splits information reveals the company's dividend history, payout ratio, and dividend yield metrics.
Overall, the data provides a comprehensive overview of the company's financial performance, stock metrics, valuation, stock price movements, and dividend policies.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been relatively stable, with gross profit ranging from around $105 billion to $169 billion.
3. Operating income has also shown a consistent growth trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has been increasing over the years, from $57.4 billion in 2020 to $97 billion in 2023.
5. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
6. The company has been able to maintain a healthy EBITDA margin, with EBITDA ranging from $81 billion to $129 billion.
7. Despite fluctuations in other income and expenses, the company has managed to sustain its profitability and increase its net income continuously.
8. The company has been effectively managing its operating expenses, with a slight increase in research and development costs over the years.
9. The company's effective tax rate has remained relatively stable, allowing it to generate significant net income.
10. The number of basic and diluted shares outstanding has remained constant over the years, indicating no significant dilution of shares.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
6. The company has been relying more on non-current assets to finance its operations, as seen in the increasing trend of non-current assets compared to current assets.
7. The company has been able to maintain a positive shareholders' equity throughout the years, indicating a healthy financial position.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with some fluctuations in key financial metrics over the years.
MACD of HEMO
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
